Tutti gli studi
Attivo ma non reclutanteFASE3INTERVENTISTICO

Uno studio su Asciminib orale rispetto ad altri TKI in pazienti adulti con nuova diagnosi di LMC-CP Ph+

Chronic myeloid leukaemia (CML) is a slow-growing type of blood cancer linked to an unusual gene change called the Philadelphia chromosome. Most people manage CML by taking daily targeted tablets that stop leukaemia cells from multiplying. This Phase 3 trial compares a new targeted drug, asciminib, against current standard treatments (such as imatinib, nilotinib, dasatinib, or bosutinib). It is designed for adults who have been diagnosed with chronic-phase CML within the past three months and have not yet started long-term treatment. Half of the participants will receive asciminib, while the other half will receive one of the standard medicines agreed upon by their doctor. The main goal is to find out if asciminib works better at clearing the cancer from the blood, causes fewer side effects, and allows some patients to eventually pause their medication safely.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE3
Sponsor
Novartis Farmaceutici
Obiettivo di iscrizione
405
Inizio
06 Ott 2021
Completamento stimato
18 Gen 2031

Risultati

Risultati di questo studio

Pubblicato Marzo 2025

I risultati di questo studio sono stati pubblicati.

Risultato principale
Percentuale di Partecipanti con Risposta Molecolare Maggiore (MMR) alla Settimana 48 - Ascimimib vs. TKI Selezionato dall'Investigatore
La risposta molecolare viene valutata utilizzando i livelli di trascrizione BCR-ABL1 misurati mediante reazione a catena della polimerasi quantitativa in tempo reale. La MMR è definita come un rapporto BCR-ABL/ABL ≤0,1% sulla scala internazionale (cioè, almeno una riduzione di 3 log rispetto a un valore di base standardizzato).
Risultati completi nel registro

Di cosa tratta questo studio?

Chronic myeloid leukaemia (CML) affects the white blood cells. In most cases, it is caused by two chromosomes swapping pieces of DNA to form the 'Philadelphia chromosome'. This creates a faulty protein that tells the bone marrow to make too many abnormal white blood cells. Standard treatments, known as tyrosine kinase inhibitors (TKIs), block this signal and have transformed CML into a manageable long-term condition for many people.

Even though current medicines work well, they do not suit everyone. Some people experience troublesome side effects such as extreme tiredness, nausea, muscle aches, or heart problems, while others find the treatment stops working over time. Asciminib is a newer type of tablet that blocks the faulty protein in a slightly different way. Scientists hope this more specific approach will control the leukaemia just as well, or even better, while causing fewer unwanted side effects.

In this trial, doctors are comparing asciminib directly against the standard medicines in newly diagnosed patients. Participants will be monitored very closely through regular blood tests. If a participant achieves an extremely deep response where the cancer becomes undetectable for a sustained period, they may be given the option to try pausing their tablets under strict medical supervision. If the cancer shows signs of returning, treatment is restarted straight away.

Punti chiave

  • The trial tests a new targeted tablet, asciminib, against current standard treatments for newly diagnosed CML.
  • Open to adults aged 18 and older diagnosed with Philadelphia chromosome-positive CML in the chronic phase within the last three months.
  • Participants are randomly split into two groups: one takes asciminib, and the other takes an existing standard medicine.
  • There is no placebo; all participants receive an active cancer treatment.
  • Patients who achieve deep remission may have the opportunity to pause their medication under close hospital monitoring.

Chi può essere idoneo?

This study is open to adults aged 18 and over who have been diagnosed with Philadelphia chromosome-positive chronic myeloid leukaemia within the last three months. Patients must be in the 'chronic phase', which means the leukaemia is in its early, slower-moving stage with low numbers of immature cells (blasts) in the blood and bone marrow.

To take part safely, participants need to be in reasonably good general health and able to carry out their daily activities. Key organs such as the kidneys, liver, and pancreas must be working adequately, and blood levels of minerals like potassium and calcium must be in a safe range.

You cannot join the study if your leukaemia has progressed beyond the chronic phase, if you have already had standard leukaemia treatment for more than a brief period, or if you have serious underlying medical conditions that could make taking the study medicines unsafe.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I am aged 18 or older.
  2. I was diagnosed with chronic myeloid leukaemia (CML) within the last three months.
  3. My leukaemia is confirmed to be Philadelphia chromosome-positive and in the chronic phase.
  4. I have not yet started long-term targeted tablet treatment for CML.
  5. My kidneys, liver, and pancreas are functioning reasonably well.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to join, you will be randomly assigned by a computer to one of two groups. One group takes asciminib once daily as a tablet on an empty stomach. The other group takes a standard daily tablet (such as imatinib, dasatinib, nilotinib, or bosutinib) chosen by your study doctor before randomisation. Neither you nor your doctor can choose your group.

You will attend regular hospital appointments, especially during the first few months. Visits will involve physical examinations, blood tests to measure leukaemia levels, heart checks (ECGs), and occasional bone marrow samples. You will also be asked to keep track of how you feel and report any side effects.

The study lasts several years. If your treatment works exceptionally well and your leukaemia reaches very low levels, you may be invited to enter a 'treatment-free' period where you pause your medication while remaining under close observation. If tests show the leukaemia is waking up, you will immediately restart treatment.

Rischi e benefici potenziali

Taking part may give you access to a promising new treatment, and you will receive regular, detailed health checks from leukaemia specialists. However, asciminib can cause side effects such as headache, tiredness, nausea, high blood pressure, or temporary drops in healthy blood cells. There is also a chance the study medicine may not work as well as standard care. Taking part is completely voluntary; you can leave the study at any time without giving a reason, and your standard NHS care will not be affected.

Luoghi (110)

  • Centri Oncologici delle Montagne Rocciose
    Codice postale verificato
    Denver, Stati Uniti
  • Specialisti in Cancro della Florida
    Codice postale verificato
    Fort Myers, Stati Uniti
  • Specialisti in Cancro della Florida Pan
    Codice postale verificato
    Tallahassee, Stati Uniti
  • Università del Kentucky
    Codice postale verificato
    Lexington, Stati Uniti
  • Centro Medico dell'Università del Massachusetts
    Codice postale verificato
    Worcester, Stati Uniti
  • Centro Medico Battista dell'Università di Wake Forest
    Codice postale verificato
    Winston-Salem, Stati Uniti
  • Centro Oncologico Williamette
    Codice postale verificato
    Eugene, Stati Uniti
  • Università delle Scienze della Salute dell'Oregon
    Codice postale verificato
    Portland, Stati Uniti
  • Avera Cancro
    Codice postale verificato
    Sioux Falls, Stati Uniti
  • Chattanooga Onc And Hem Assoc PC
    Codice postale verificato
    Chattanooga, Stati Uniti
  • Texas Oncology
    Codice postale verificato
    Amarillo, Stati Uniti
  • Texas Oncology-Baylor USO
    Codice postale verificato
    Dallas, Stati Uniti

Domande comuni

What is the difference between asciminib and standard CML tablets?

Standard tablets attach to the active site of the cancer-causing protein to switch it off. Asciminib binds to a different pocket on the protein (known as the myristoyl pocket), which shuts it down in a more targeted way, potentially causing fewer side effects.

Can I choose which medicine I receive?

No. A computer randomly assigns you to either asciminib or standard treatment so the trial remains fair and scientifically accurate. However, if assigned to standard treatment, your doctor selects the best standard tablet for you beforehand.

Will I be given a dummy pill (placebo)?

No. There is no placebo in this study. Every participant receives an active, proven cancer treatment or the new study medicine.

What is 'treatment-free remission'?

This is a safe, medically supervised break from daily tablets. It is only offered to people whose leukaemia levels have dropped to undetectable levels for an extended period, with frequent blood tests to monitor safety.

What happens if my cancer gets worse during the study?

Your medical team will monitor you closely. If the assigned medicine is not controlling your leukaemia, you will be taken off the study medicine and switched to another proven treatment right away.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.